Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Amalgamated Bank

Amalgamated Bank reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,351 shares of the life sciences company’s stock after selling 573 shares during the period. Amalgamated Bank’s holdings in Illumina were worth $10,069,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Bleakley Financial Group LLC acquired a new position in shares of Illumina during the fourth quarter worth $751,000. Zacks Investment Management acquired a new stake in Illumina in the third quarter valued at $2,924,000. Van ECK Associates Corp raised its holdings in Illumina by 17.5% in the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock valued at $20,347,000 after acquiring an additional 22,718 shares in the last quarter. Strategic Financial Concepts LLC acquired a new stake in Illumina in the fourth quarter valued at $1,464,000. Finally, Allworth Financial LP raised its holdings in Illumina by 720.7% in the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after acquiring an additional 6,263 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ILMN has been the topic of several recent analyst reports. UBS Group upped their price target on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Robert W. Baird upped their price target on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Barclays cut shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their price target for the company from $130.00 to $100.00 in a report on Monday, February 10th. Citigroup lowered shares of Illumina from a “buy” rating to a “neutral” rating and lowered their target price for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. Finally, Stephens boosted their target price on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $159.45.

Illumina Stock Performance

Shares of ILMN opened at $95.73 on Wednesday. The firm has a 50-day moving average price of $126.02 and a 200 day moving average price of $133.80. The firm has a market capitalization of $15.16 billion, a PE ratio of -12.46, a P/E/G ratio of 1.60 and a beta of 1.10. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 52-week low of $91.92 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.